# US 2026/0090969 A1 · Compositions that protect cells from oxidative and mitochondrial stress

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0090969 A1
- Document ID: US20260090969A1
- Status: Published application
- Kind: A1
- Application number: 19/255,485
- Filed: 2025-06-30
- Published: 2026-04-02
- Earliest claimed: 2018-07-10
- Assignees: Nuchido Limited
- Applicants: Nuchido Limited
- Inventors: Nichola Jane Conlon; Malcolm Philip Young
- Web page: https://patentgrep.com/patent/US20260090969A1

## CPC

- A61K 8/675: {Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde (tocopheryl nicotinate A61K8/678)}
- A61K 8/27: Zinc; Compounds thereof
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/4986: {with sulfur as the only hetero atom}
- A61K 8/676: {Ascorbic acid, i.e. vitamin C}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 33/30: Zinc; Compounds thereof
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/92: Oral administration
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

## Claims

### Claim at position 1

-65. (canceled)

### Claim 66

A composition comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACTI peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof); and derivatives thereof; and any combination thereof.

### Claim 67

A method of enhancing cell resistance to DNA damage, oxidative stress, mitochondrial dysfunction, or improving DNA repair capacity, said method comprising the administration to an individual of an effective amount of a composition comprising an effective amount of from 150 mg to 700 mg niacinamide; from 150 mg to 700 mg quercetin or the derivative rutin; zinc (including salts thereof); ascorbic acid; from 1 mg to 1,000 mg parsley or the derivative apigenin; and from 150 mg to 700 mg alpha-lipoic acid.

### Claim 68 (depends on 67)

A method according to claim 67 for use in enhancing cell resistance to DNA damage.

### Claim 69 (depends on 67)

A method according to claim 67 for use in enhancing cell resistance to oxidative stress.

### Claim 70 (depends on 67)

A method according to claim 67 for use in enhancing cell resistance to mitochondrial dysfunction.

### Claim 71 (depends on 67)

A method according to claim 67 for use in improving a cell's DNA repair capacity.

### Claim 72 (depends on 67)

A method according to claim 67 wherein the method comprises enhancing cell resistance to DNA damage, oxidative stress, mitochondrial dysfunction, and improving DNA repair capacity.

### Claim 73 (depends on 67)

A method according to claim 67 wherein the method comprises the mitigation, alleviation or improvement of the effects of ageing in a host.

### Claim 74 (depends on 73)

A method according to claim 73 wherein the method of mitigation, alleviation or improvement of the effects of ageing in a host is by improving a cell's resistance to DNA damage and/or enhancing the cell's DNA repair capacity.

### Claim 75 (depends on 73)

A method according to claim 73 wherein the effects of ageing include age related skin conditions, skin conditions related to sun exposure, skin conditions related to pollution exposure, skin conditions related to oxidative stress, and skin conditions related to lifestyle choices, diet, alcohol and/or smoking.

### Claim 76 (depends on 67)

A method according to claim 67 wherein the method comprises the mitigation, alleviation or improvement of inflammatory skin disorders and skin conditions related autoimmune disease skin disorders.

### Claim 77 (depends on 76)

A method according to claim 76 wherein the skin condition is an age related skin condition.

### Claim 78 (depends on 77)

A method according to claim 77 wherein the age related skin condition includes one or more of sagging, wrinkles, skin elasticity, skin ageing, skin moisture, wounds, acne, skin darkening, skin whitening, pigmentation, age-spots, loss of radiance, puffiness, uneven skin tone, redness, rosacea, loss of barrier function, loss of skin resilience, loss of firmness, stretch-marks, cellulite and dryness.

### Claim 79 (depends on 77)

A method according to claim 77 wherein the skin condition is caused by sun exposure.

### Claim 80 (depends on 77)

A method according to claim 77 wherein the skin condition includes one or more of actinic keratoses, freckles, lentigines or age spots, moles, photosensitivity, polymorphous light eruption, seborrheic keratoses, skin cancer (melanoma, squamous cell carcinoma, basal cell carcinoma), solar elastosis or wrinkles and sun burn.

### Claim 81 (depends on 76)

A method according to claim 76 wherein the skin condition is caused by inflammation.

### Claim 82 (depends on 76)

A method according to claim 76 wherein the skin condition includes one or more of acne, asteatotic eczema, atopic dermatitis, contact dermatitis, discoid eczema, eczematous drug eruptions, erythema multiforme, erythroderma, gravitational/varicose eczema, hand eczema, keratosis lichenoides chronica, lichen nitidus, lichen planus, lichen simplex, lichen striatus, mycosis fungoides, pityriasis lichenoides, psoriasis, seborrheic dermatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis and vasculitis.

### Claim 83 (depends on 76)

A method according to claim 76 wherein the skin condition is caused by an autoimmune disease.

### Claim 84 (depends on 67)

A method according to claim 67 for topical, transdermal, oral or parenteral administration.

### Claim 85 (depends on 84)

A method according to claim 84 for topical administration.

### Claim 86 (depends on 85)

A method according to claim 85 in the form of an aqueous solution, suspension, serum, ointment, cream, gel, sprayable formulation, transdermal patch or bandage.

### Claim 87 (depends on 84)

A method according to claim 84 for parenteral administration.

### Claim 88 (depends on 87)

A method according to claim 87 for parenteral administration in the form of an intramuscular, intravenous, subcutaneous, intraperitoneal, local or transdermal injections.

### Claim 89 (depends on 84)

A method according to claim 84 for transdermal administration.

### Claim 90 (depends on 89)

A method according to claim 89 in the form of an aqueous solution, suspension, ointment, cream, gel, sprayable formulation, transdermal patch or bandage.

### Claim 91 (depends on 73)

A method according to claim 73 wherein the effects of ageing include increased frailty, loss of resilience, loss of muscle strength, loss of muscle endurance, loss of energy, loss of cognitive sharpness or loss of memory.

### Claim 92 (depends on 73)

A method according to claim 73 wherein the effects of ageing include atherosclerosis, cardiovascular disease, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes, hypertension or Alzheimer's disease.

### Claim 93 (depends on 67)

A method according to claim 67 wherein the composition includes an effective amount of one or more glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid and glycyrrhizin.